EpiCept Corporation (Nasdaq and Nasdaq OMX Stockholm Exchange: EPCT) today announced the commercial launch of Ceplene (R) (histamine dihydrochloride) in Germany. The launch is being conducted by Meda AB, (OMX Nordic Exchange: MEDA-A-ST) as part of an exclusive commercialization agreement for Ceplene signed by the two companies in January 2010. Meda is a leading international specialty pharmaceutical company with products sold in 120 countries worldwide and a marketing organization of about 1,200 people throughout Europe.
Germany is the second country in the European Union in which Ceplene has become commercially available, following the product's launch in the United Kingdom in April, 2010. Ceplene will be shipped in cartons of 14 vials (enough for 1 week's therapy). In support of the launch of Ceplene throughout the European Union, Meda will be exhibiting at the European Hematology Association's 15th Congress in Barcelona, Spain from June 10-13, 2010.